Stoke Therapeutics: Treatment outcomes of STK-001 for Dravet syndrome


In this video, Dr Scott Perry, MD of Cook Children’s Medical Center presents data from multiple ongoing clinical studies that support the potential of STK-001, an antisense oligonucleotide, as the first disease-modifying treatment for Dravet syndrome. This presentation was recorded at the 2023 International Epilepsy Congress. For additional information about STK-001 or Stoke Therapeutics, please contact Stoke Therapeutics at or visit

Guest: Dr. Scott Perry, Cook Children’s Medical Center